Arcus Biosciences, Inc. (RCUS) — Analyst outlook / Analyst consensus target is. Based on 18 analyst ratings, the consensus is bullish — 15 Buy, 3 Hold.
The consensus price target is $28.00 (low: $20.00, high: $35.00), representing an upside of 21.7% from the current price $23.01.
Analysts estimate Earnings Per Share (EPS) of $-3.41 and revenue of $0.26B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.14 vs est $-3.41 (beat +7.9%). 2025: actual $-3.29 vs est $-3.55 (beat +7.4%). Analyst accuracy: 92%.
RCUS Stock — 12-Month Price Forecast
$28.00
▲ +21.69% Upside
Average Price Target
Based on 18 Wall Street analysts offering 12-month price targets for Arcus Biosciences, Inc., the average price target is $28.00, with a high forecast of $35.00, and a low forecast of $20.00.
The average price target represents a +21.69% change from the last price of $23.01.
Highest Price Target
$35.00
Average Price Target
$28.00
Lowest Price Target
$20.00
RCUS Analyst Ratings
Buy
Based on 18 analysts giving stock ratings to Arcus Biosciences, Inc. in the past 3 months
EPS Estimates — RCUS
92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.14
vs Est –$3.41
▲ 8.6% off
2025
Actual –$3.29
vs Est –$3.55
▲ 8.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — RCUS
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.258B
vs Est $0.262B
▼ 1.4% off
2025
Actual $0.247B
vs Est $0.247B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
